Spring til hovednavigation Spring til søgning Spring til hovedindhold

Can we identify allergic rhinitis from administrative data: A validation study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Background: Important insights on, for example, prevalence, disease progression, and treatment of allergic rhinitis can be obtained from large-scale database studies if researchers are able to identify allergic individuals. We aimed to assess the validity of 13 different algorithms based on Danish nationwide prescription and/or hospital data to identify adults with allergic rhinitis. Methods: Our primary gold standard of allergic rhinitis was a positive serum specific IgE (≥0.35) and self-reported nasal symptoms retrieved from two general health examination studies conducted in Danish adults (18-69 years) during 2006 to 2008 (n = 3416) and 2012 to 2015 (n = 7237). The secondary gold standard of allergic rhinitis was self-reported physician diagnosis. We calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value, and corresponding 95% confidence intervals (95% CI) for each register-based algorithm in the two time periods. Results: Sensitivity (≤0.40) was low for all algorithms irrespective of definition of allergic rhinitis (gold standard) or time period. The highest PPVs were obtained for algorithms requiring both antihistamines and intranasal corticosteroids; yielding a PPV of 0.69 (0.62-0.75) and a corresponding sensitivity of 0.10 (0.09-0.12) for the primary gold standard of allergic rhinitis in 2012 to 2015. Conclusion: Algorithms based on both antihistamines and intranasal corticosteroids yielded the highest PPVs. However, the PPVs were still moderate and came at the expense of low sensitivity when applying the strict primary gold standard (sIgE and nasal symptom).

OriginalsprogEngelsk
TidsskriftPharmacoepidemiology and Drug Safety
Vol/bind29
Udgave nummer11
Sider (fra-til)1423-1431
Antal sider9
ISSN1053-8569
DOI
StatusUdgivet - 2020

Finansiering

Katja Biering Leth‐Møller was financially supported by Innovation Fund Denmark. Tea Skaaby was funded by the Lundbeckfonden. The authors thank the project team behind Health2006 and DanFunD at the Research Center for Prevention and Health (now: Center for Clinical Research and Prevention) for their invaluable commitment in collecting and assuring data. The DanFunD Steering Committee consisting of Prof. Torben Jørgensen, MD, DMSc (principal investigator), Prof. Per Fink, MD, DMSc, Lene Falgaard Eplov MD, PhD (senior consultant), Betina Heinsbæk Thuesen, MSc, PhD, Susanne Brix Pedersen, MSc, PhD, Michael Eriksen Benros, MD, PhD, and Thomas M. Dantoft, MSc, PhD (DanFunD scientific officer). The DanFunD cohort was funded by the Danish Foundations, The Lundbeckfonden (grant number R155‐2013‐14070) and TrygFonden (grant number 7‐11‐0213). The funding sources had no role in the design, conduct, or reporting of the study.

Citationsformater